Inflammation, Endothelial Permeability, and the Vulnerable Plaque
The past 10 to 15 years have witnessed a tremendous interest in developing and validating noninvasive imaging techniques aimed at quantifying features of atherosclerotic plaque vulnerability in humans, most notably plaque inflammation. Among these, magnetic resonance imaging (MRI) with iron oxide nanoparticles has been widely investigated over the years as a mean to detect this feature of high-risk plaques. 1
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Iron Oxide Nanoparticles Imaging of Plaque Inflammation
Iron oxide nanoparticles are particles containing an iron oxide core. Based on their size, they are subdivided into several types, better suited for different applications (eg, intravascular versus tissue imaging). 2 Their tissue accumulation causes local magnetic field inhomogeneities that can be measured by MRI. 2 Alternatively, iron oxides (such as, the dextran-coated cross-linked iron oxide nanoparticles [CLIO] , used in this work) 3 can be labeled with radioisotopes or fluorophores and functionalized as multimodality imaging agents detectable by positron emission tomography or near-infrared fluorescence (NIRF) imaging, alone or in combination. 4 Iron oxides can be used as non-targeted agents, avidly phagocytized by inflammatory cells and cells of the reticuloendothelial system, 2 or can be labeled to target and image specific molecules involved in disease processes (some examples in atherosclerosis are iron oxides targeted to oxidation-specific epitopes or to adhesion molecules on endothelial cells). 5 Although targeted and functionalized nanoparticles are typically used in animal models, some nontargeted iron oxides are commercially available. Ferumoxtran-10 and ferumoxytol, an agent currently approved only for the treatment of iron-deficient anemia in patients with chronic kidney disease, are ultrasmall superparamagnetic iron oxides that are currently or have been previously clinically approved and whose use has been investigated to track plaque inflammation. 6 The use of these and other iron oxides for pre clinical and clinical imaging of cardiovascular disease has been described in hundreds of publications, of which we give some examples.
In several studies, uptake of ferumoxtran-10 was demonstrated in the symptomatic and contralateral asymptomatic carotid artery of patients with carotid 7 and coronary artery disease. 8 No correlation was found between ferumoxtran-10 uptake and carotid stenosis. 9 The ATHEROMA study (Atorvastatin Therapy: Effects on Reduction of Macrophage Activity) showed a reduction in ferumoxtran-10 uptake in the human carotid arteries after 12 weeks of treatment with high dose (80 mg/d) but not low (10 mg/d) dose atorvastatin, 10 suggestive of a reduction in plaque inflammation. Pre-clinical studies in animal models have offered further insights into the role of iron oxides for plaque imaging. A lower accumulation of P904, an ultrasmall superparamagnetic iron oxide particle with fast blood clearance, was shown in aortic plaques of atherosclerotic mice after treatment with irbesartan. 11 P904 accumulation correlated with ΔT2* values and with macrophage-covered area by immunohistological analysis. 11 In rabbits, both ferumoxtran-10 and ferumoxytol 12 were found to accumulate in aortic plaques. In hereditary hyperlipidemic rabbits, a low endothelial sheer stress (calculated using computational fluid dynamics of computed tomographic images) and P904 accumulation assessed by MRI were found to be independent predictors of plaque progression. 13 A different study using dextran-coated monocrystalline iron oxide nanoparticles demonstrated vessel wall accumulation in a similar rabbit model, which correlated with plaque macrophages content, and was reduced on regression of plaque inflammation after treatment with rosuvastatin. 14 Although iron oxides have been widely used in these studies as macrophage imaging agents, as already mentioned in the article by Stein-Merlob et al 15 in this issue of Circulation: Cardiovascular Imaging, some animal studies have raised questions on their pattern of deposition within the plaque and their cellular specificity. As an additional example, a murine study 16 showed a reduction in ferumoxtran-10 uptake, rather than macrophages content, after treatment with a p38 mitogen-activated protein kinases inhibitor. Another study in rabbits 17 showed that 15 nm fractionated, but not nonfractionated, feridex (a superparamagnetic iron oxide) gets deposited in atherosclerotic plaques in this model, thereby suggesting that iron oxides particle size should be further investigated to optimize plaque macrophages targeting. Iron Oxides and Atherothrombosis
Investigating the Intraplaque and Cellular Distribution of Iron Oxides: CLIO-CyAm7 Nanoparticles
In this article, Stein-Merlob et al 15 
Endothelial Permeability, CLIO-CyAm7 Accumulation, and Arterial Thrombosis
To test this hypothesis, a group of 7 rabbits was coinjected with CLIO-CyAm7 and Evans blue, a fluorescent albuminbinding dye that is known to accumulate in areas of increased permeability. Evans blue and CLIO-CyAm7 plaque accumulation were found to be highly correlated (r=0.64; P=0.003). Based on these findings, the authors proceeded to further investigate the possible relationship between increased plaque permeability and atheroma CLIO-CyAm7 deposition as predictive traits of plaques prone to thrombosis. An additional 15 rabbits were injected with CLIO-CyAm7 and imaged 24 hours afterward with intravascular in vivo NIRF, which confirmed CLIO-CyAm7 deposition in atheromas identified by intravascular ultrasound. After imaging, rabbits underwent a well-validated triggering procedure with intraperitoneal injection of viper venum and histamine to induce arterial thrombosis. Follow-up intravascular ultrasound after triggering revealed the formation of thrombotic areas in 67% of the animals, confirmed by histology. Quantitative analysis of pretriggering intravascular in vivo NIRF revealed higher CLIO-CyAm7 accumulation in thrombotic versus nonthrombotic plaques at the post trigger intravascular ultrasound. Receiver operating characteristic curves analysis revealed that the positive predictive value of pre triggering CLIO-CyAm7 aortic deposition for plaque thrombosis was 59.4% (confidence interval, 40.6%-76.3%) and the negative predictive value was 84.0% (confidence interval, 63.9%-95.4%).
Imaging Inflammation and Endothelial Permeability as Predictors of Atherothrombosis: Current Status and Future Directions
This important study by Stein-Merlob et al 15 sheds some light into the intraplaque distribution and cellular specificity of multimodality-functionalized CLIOs. CLIOs plaque distribution is found to be inhomogeneous along the plaque luminal circumference and preferentially around the superficial intima. Accumulation within deeper plaque regions is colocalized with plaque neovessels in these same areas. Furthermore, ex vivo investigation demonstrates a relationship between plaque endothelial permeability and nanoparticles accumulations and a predictive value of CLIO-CyAm7 deposition for arterial thrombosis in the rabbit model. Importantly, the authors demonstrated feasibility of using intravascular NIRF to quantify CLIO-CyAm7 accumulation in vivo in a vessel of comparable size to the human coronary arteries. 18 These findings indicate that in the near future, in vivo NIRF, alone or in combination with other intravascular imaging modality, may further enhance our ability to characterize atheromas in this challenging vascular territory. The mechanisms of uptake and intraplaque distribution of nanoparticles used for diagnostic or theranostic purposes, including but not limited to iron oxides, are the subject of active investigation. A similar dependency of nanoparticles accumulation to plaque permeability has been previously demonstrated for another near-infrared fluorophore Cy7labeled long circulating liposomal nanoparticles also in the rabbit model. 19 In this case, nanoparticles vessel wall uptake was found to correlate with both ex vivo NIRF imaging with Evans blue and the in vivo quantification of endothelial permeability with dynamic contrast-enhanced MRI. Interestingly, in this specific case, the correlation was stronger with nanoparticles accumulation half an hour after injection and was found to weaken and then disappear at 6 and 24 hours after injection, reflecting the particles gradual diffusion within the plaque from the luminal side.
The predictive value of endothelial permeability for plaque thrombosis has also been recently investigated in rabbits using in vivo T1 mapping with MRI after injection of a gadoliniumbased, albumin-binding contrast agent, performed pre-and post-triggering to induce atherothrombosis. 20 Similarly to what is presented here, the authors found that rupture-prone plaques are characterized by increased endothelial permeability before triggering. Receiver operating characteristic analysis revealed that this parameter was highly predictive of plaque thrombosis in the post-trigger scans.
Here, CLIOs plaque uptake is shown to depend on both endothelial permeability and internalization by plaque macrophages and other cells type, making its predictive value for arterial thrombosis potentially more complex to interpret. New discoveries on the relative contributions of endothelial dysfunction, plaque neovascularization, permeability, and inflammation to atherogenesis will allow us to better understand the predictive value of iron oxides plaque accumulation for vulnerability, thrombosis, rupture, and cardiovascular events. In the pre-clinical arena, the flexibility to functionalize Iron Oxides and Atherothrombosis these particles into multimodality agents (as shown here) will allow gathering tremendous mechanistic insights on their plaque-and cell-targeting properties in the context of atheroma progression or regression on treatment. This information will be crucial to understand the added value and complementary information of plaque iron oxides imaging in humans in comparison with the other clinical imaging techniques available to characterize plaque vulnerability. 1, 19, 20 
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